Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

NCT02771054 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

HIV

Interventions

DRUG: TAF/FTC

Sponsor

Göteborg University